DiSaia P J
Cancer. 1976 Jul;38(1 SUPPL):566-80. doi: 10.1002/1097-0142(197607)38:1<566::aid-cncr2820380181>3.0.co;2-o.
Highlights of recent advances in the field of gynecologic tumor immunology are presented in an effort to demonstrate that at least some cancers of the female genitalia evoke an immune response that can be quantitated in the laboratory. The overview will discuss investigations into the various in vitro assays of both humoral and cell-mediated immunity. The concept of clinical testing of delayed hypersensitivity reactions as it relates to the clinical outcome of the patients with malignancy is presented. Along this line, preliminary studies at our own institution are reviewed in an attempt to establish a rough correlation between patients with a healthy outcome and patients with a strong immunologic index as manifested by skin testing. A progress report on the isolation of tumor-associated antigens in cancer of the cervix and ovary is presented. The prevalence of carcinoembryonic antigen in the plasma of patients with gynecological malignancy is then discussed. Finally, approaches to immunotherapy are discussed, with a suggestion as to future directions.
本文介绍了妇科肿瘤免疫学领域近期进展的要点，以证明至少某些女性生殖系统癌症会引发一种可在实验室中进行定量的免疫反应。概述将讨论对体液免疫和细胞介导免疫的各种体外检测方法的研究。还介绍了与恶性肿瘤患者临床结局相关的迟发型超敏反应临床检测概念。在此方面，回顾了我们自己机构的初步研究，试图在预后良好的患者与通过皮肤试验表现出强大免疫指标的患者之间建立大致的相关性。展示了关于宫颈癌和卵巢癌中肿瘤相关抗原分离的进展报告。随后讨论了妇科恶性肿瘤患者血浆中癌胚抗原的流行情况。最后，讨论了免疫治疗方法，并对未来方向提出了建议。
